Post Hoc analyses of intention-to-treat population in phase III comparison of NovoTTF-100A™ system versus best physician's choice chemotherapy.

We performed a treatment-based analysis of data from the pivotal phase III trial of the NovoTTF-100A System™ versus best physician's choice (BPC) chemotherapy in patients with recurrent glioblastoma multiforme (GBM), with particular focus on efficacy in patients using NovoTTF Therapy as intended. Median overall survival (OS) was compared for recurrent GBM patients receiving at least one full cycle of treatment with NovoTTF-100A System or BPC chemotherapy (modified intention-to-treat [mITT] population) in the recently reported phase III trial. The relationship between NovoTTF-100A System compliance and OS was evaluated in the ITT population. Kaplan-Meier analyses examined treatment-related differences in OS for various patient subgroups. Median OS was significantly higher in patients receiving≥1 course of NovoTTF Therapy versus BPC (7.7 v 5.9 months; hazard ratio, 0.69; 95% confidence interval [CI], 0.52-0.91; P = .0093). Median OS was also significantly higher in patients receiving NovoTTF Therapy with a maximal monthly compliance rate≥75% (≥18 hours daily) versus those with a<75% compliance rate (7.7 v 4.5 months; P = .042), and Kaplan-Meier analysis demonstrated a significant trend for improved median OS with higher compliance (P = .039). Additional post hoc analysis showed significantly higher median OS with NovoTTF Therapy than with BPC for patients with prior low-grade glioma, tumor size≥18 cm(2), Karnofsky performance status≥80, and those who had previously failed bevacizumab therapy. When used as intended in mITT patients with recurrent GBM, NovoTTF Therapy provides an OS benefit compared with chemotherapy in patients with recurrent GBM. This contrasts with the equivalent efficacy reported previously based on analysis of all randomized ITT subjects, including many who did not receive a full cycle of treatment. Higher NovoTTF Therapy compliance corresponds with greater survival benefit in the present study.

[1]  C D Naylor,et al.  Subgroups, treatment effects, and baseline risks: some lessons from major cardiovascular trials. , 2000, American heart journal.

[2]  E. Dekel,et al.  Disruption of cancer cell replication by alternating electric fields. , 2004, Cancer research.

[3]  P. Rothwell.  Subgroup analysis in randomised controlled trials: importance, indications, and interpretation , 2005, The Lancet.

[4]  Stephen W Lagakos,et al.  Statistics in medicine--reporting of subgroup analyses in clinical trials. , 2007, The New England journal of medicine.

[5]  E. Dekel,et al.  Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors , 2007, Proceedings of the National Academy of Sciences.

[6]  John Sampson,et al.  Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  T. Mikkelsen,et al.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Laura A. Sullivan,et al.  Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts , 2009, Molecular Cancer Therapeutics.

[9]  J. Vymazal,et al.  Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields) , 2009, BMC medical physics.

[10]  John A Butman,et al.  Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  E. Kirson,et al.  TTFields alone and in combination with chemotherapeutic agents effectively reduce the viability of MDR cell sub-lines that over-express ABC transporters , 2010, BMC Cancer.

[12]  Steven Piantadosi,et al.  Survival of Patients with Newly Diagnosed Glioblastoma Treated with Radiation and Temozolomide in Research Studies in the United States , 2010, Clinical Cancer Research.

[13]  Uri Weinberg,et al.  Tumor treating fields: concept, evidence and future , 2011, Expert opinion on investigational drugs.

[14]  M. Gilbert.  Recurrent glioblastoma: a fresh look at current therapies and emerging novel approaches. , 2011, Seminars in Oncology.

[15]  P. Gutin,et al.  NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. , 2012, European journal of cancer.

[16]  Philip H Gutin,et al.  Noninvasive application of alternating electric fields in glioblastoma: a fourth cancer treatment modality. , 2012, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[17]  J. Baehring,et al.  Glioblastoma multiforme: overview of current treatment and future perspectives. , 2012, Hematology/oncology clinics of North America.

[18]  E. Wong,et al.  NovoTTF-100A: a new treatment modality for recurrent glioblastoma , 2012, Expert review of neurotherapeutics.

[19]  J. Keller,et al.  Long-term survival of patients suffering from glioblastoma multiforme treated with tumor-treating fields , 2012, World Journal of Surgical Oncology.

[20]  Y. Narita.  Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors. , 2013, Japanese journal of clinical oncology.

[21]  Karriem S. Watson,et al.  Delayed response and survival from NovoTTF-100A in recurrent GBM , 2013, Medical Oncology.

[22]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. , 2013, Neuro-oncology.

[23]  K. Aldape,et al.  Using the molecular classification of glioblastoma to inform personalized treatment , 2014, The Journal of pathology.

[24]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[25]  F. Lieberman,et al.  Response assessment of NovoTTF-100A versus best physician's choice chemotherapy in recurrent glioblastoma , 2013, Cancer medicine.